EUVIMEDEUVIMED entdecken
Open Access

Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants

Shi Liu iD, Eileen J Daley, Lauren My-Linh Tran iD, Zhen Yu iD, Monica Reyes, Thomas Dean, Ashok Khatri, Paul M Levine, Aaron T Balana, Matthew R Pratt iD, Harald Jüppner, Samuel H Gellman iD und 1 weitere

Journal of the American Chemical Society · 2024

DOI: 10.1021/jacs.3c09694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2024. Verfasst von Shi Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States. Hauptthemen laut MEDLINE: Drug Inverse Agonism, Receptor, Parathyroid Hormone, Type 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parathyroid hormone 1 receptor (PTH1R) plays a key role in mediating calcium homeostasis and bone development, and aberrant PTH1R activity underlies several human diseases. Peptidic PTH1R antagonists and inverse agonists have therapeutic potential in treating these diseases, but their poor pharmacokinetics and pharmacodynamics undermine their in vivo efficacy. Herein, we report the use of a backbone-modification strategy to design a peptidic PTH1R inhibitor that displays prolonged activity as an antagonist of wild-type PTH1R and an inverse agonist of the constitutively active PTH1R-H223R mutant both in vitro and in vivo. This peptide may be of interest for the future development of therapeutic agents that ameliorate PTH1R malfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Inverse AgonismReceptor, Parathyroid Hormone, Type 1HumansPeptidesParathyroid Hormone

Substanzen

Receptor, Parathyroid Hormone, Type 1PeptidesParathyroid HormonePTH1R protein, human

Autor:innen und Institutionen

  • Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
  • Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
  • Departments of Chemistry and Biological Sciences, University of Southern California, Los Angeles, California 90089, United States.
  • Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.

ORCID-Profile: Shi Liu, Lauren My-Linh Tran, Zhen Yu, Matthew R Pratt, Samuel H Gellman

Förderung

  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIAMS NIH HHS
  • Foundation for the National Institutes of Health
  • William F. Vilas Trust Estate
  • Chemistry-Biology Interface Training

Zitieren

APA

Liu, S., Daley, E. J., Tran, L. M., Yu, Z., Reyes, M., Dean, T., Khatri, A., Levine, P. M., Balana, A. T., Pratt, M. R., Jüppner, H., Gellman, S. H., & Gardella, T. J. (2024). Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.3c09694

Vancouver

Liu S, Daley EJ, Tran LM, Yu Z, Reyes M, Dean T, et al. Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.3c09694

BibTeX
@article{Liu2024,
  author = {Liu, Shi and Daley, Eileen J and Tran, Lauren My-Linh and Yu, Zhen and Reyes, Monica and Dean, Thomas and Khatri, Ashok and Levine, Paul M and Balana, Aaron T and Pratt, Matthew R and Jüppner, Harald and Gellman, Samuel H and Gardella, Thomas J},
  title = {Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants},
  journal = {Journal of the American Chemical Society},
  year = {2024},
  doi = {10.1021/jacs.3c09694}
}
Kostenlos starten →